Document is current
Any future updates will be listed below
-
Authors
Chabanon, Roman M.
Danlos, François-Xavier
Ouali, Kaissa
Postel-Vinay, Sophie
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (INCa, 2023-165-PLBIO23-139;INCa18465)
Institut National Du Cancer (INCa, 2023-165-PLBIO23-139;INCa18465)
Fondation ARC pour la Recherche sur le Cancer (ARCPGA2023010005866_6378)
Fondation ARC pour la Recherche sur le Cancer (ARCPGA2023010005866_6378)
Association Ruban Rose (Prix Ruban Rose Avenir 2023 awarded to Dr. Roman Chabanon)
European Research Council (Starting Grant, ERC-StG TargetSWITCH 101077864)
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 30 June 2025
First Online: 4 November 2025
Declarations
:
: RMC/SPV are named inventors on a patent describing the use of ADAR1 inhibitors as anti-cancer agents. As part of the Drug Development Department (DITEP), SPV/FXD/KO are principal investigators or sub-investigators of clinical trials from Abbvie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly, Exelixis, Forma, Gamamabs, Genentech, Inc., Glaxosmithkline, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharm. Dev., Inc., Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro Inc, and Xencor. SPV has received research funding from Merck KGaA, Boehringer Ingelheim, Hoffman La Roche and AstraZeneca for unrelated research projects. SPV has participated to advisory boards for Merck KGaA, Daiichi and AMGEN.
